Anavex Life Sciences Corp. AVXL
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a CNS/neurology/psychiatry drug developer. Its lead program, ANAVEX 2-73 (blarcamesine), is in Phase 1 for Early Alzheimer's disease; Rett syndrome; Fragile X syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ANAVEX 2-73 (blarcamesine) | Early Alzheimer's disease (AD IND submitted Mar 2026; ADME and DDI clinical pharmacology studies underway; Phase 3 design to be agreed with FDA) | small molecule | Phase 1 |
| ANAVEX 2-73 (blarcamesine) | Rett syndrome (Phase 3 ANAVEX2-73-RS-005, ~170 pts, not yet initiated) | small molecule | Phase 1 |
| ANAVEX 3-71 | Frontotemporal dementia / schizophrenia (Phase 1 FTD; development paused) | small molecule | Phase 1 |
| ANAVEX 2-73 (blarcamesine) | Fragile X syndrome (IND planned Sept 2026) | small molecule | Pre-clinical |
| ANAVEX 1-41 | Neurodegenerative disease (paused) | small molecule | Pre-clinical |
| ANAVEX 1066 | Neuropathic and visceral pain (paused) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026positive DDI study fully enrolled with 65 healthy volunteers on 30 mg blarcamesine; clinical conduct complete, no serious adverse events on preliminary observation.
Based on preliminary observations, no serious adverse events were reported.
Filing - Oct 15, 2026completed enrollment Anavex completed clinical conduct of ADME study with 8 participants receiving 30 mg blarcamesine, with no serious adverse events reported based on preliminary observations.
The last participant completed the study in mid-October, concluding clinical conduct.
Filing - Oct 15, 2026approval FDA cleared Anavex's IND application for blarcamesine in Fragile X syndrome, which has received Orphan Drug Designation.
as previously announced on October 15, 2026, the FDA has cleared the IND.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.